Clonality of CD4+ Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma

Melanoma and Skin CancerT Cells

Decline of PD-1 positive circulating T regulatory cells predicting more favorable clinical outcome of melanoma patients under immune checkpoint blockade

Br J Dermatol.

Gambichler T, Schröter U, Höxtermann S, Susok L, Stockfleth E, Becker JC

doi: 10.1111/bjd.18379.

Melanoma and Skin Cancer

Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study

Eur J Cancer

Umeda Y, Yoshikawa S, Kiniwa Y, Maekawa T, Yamasaki O, Isei T, Matsushita S, Nomura M, Nakai Y, Fukushima S, Saito S, Takenouchi T, Tanaka R, Kato H, Otsuka A, Matsuya T, Baba N, Nagase K, Inozume T, Onuma T, Kuwatsuka Y, Fujimoto N, Kaneko T, Onishi M, Namikawa K, Yamazaki N, Nakamura Y

doi: 10.1016/j.ejca.2021.08.034

Melanoma and Skin CancerImmunotherapy

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

Nat Med.

Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, Dummer R, Robinson MD, Levesque MP, Becher B

doi: 10.1038/nm.4466.

T Cells

The helminth-derived peptide GK-1 induces an anti-tumoral CD8 T cell response associated with downregulation of the PD-1/PD-L1 pathway

Clin Immunol.

Rodríguez-Rodríguez N, Madera-Salcedo IK, Bugarin-Estrada E, Sánchez-Miranda E, Torres-García D, Cervantes-Torres J, Fragoso G, Rosetti F, Crispín JC, Sciutto E

doi: 10.1016/j.clim.

Melanoma and Skin Cancer

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

N Engl J Med.

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J

doi: 10.1056/NEJMoa1709684.

Melanoma and Skin Cancer

PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma

Melanoma Res

Marcaillou M, Linder C, Chaltiel L, Sibaud V, Pagès C, Modesto A, Chira C, Dalmasso C, Boulinguez S, Bedane C, Meyer N

doi: 10.1097/CMR.0000000000000700

Melanoma and Skin Cancer

Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma

Eur J Cancer

Tang B, Mo J, Yan X, Duan R, Chi Z, Cui C, Si L, Kong Y, Mao L, Li S, Zhou L, Lian B, Wang X, Bai X, Xu H, Li C, Dai J, Guo J, Sheng X

doi: 10.1016/j.ejca.2021.07.018

Melanoma and Skin CancerImmunotherapy

Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma

Cancer Immunol Res.

Hogan SA, Courtier A, Cheng PF, Jaberg-Bentele NF, Goldinger SM, Manuel M, Perez S, Plantier N, Mouret JF, Nguyen-Kim TDL, Raaijmakers MIG, Kvistborg P, Pasqual N, Haanen JBAG, Dummer R, Levesque MP

doi: 10.1158/2326-6066.CIR-18-0136.

Melanoma and Skin Cancer

Association of combined PD-L1 expression and tumor-infiltrating lymphocytes features with survival and treatment outcomes in patients with metastatic melanoma

J Eur Acad Dermatol Venereol.

Bence C, Hofman V, Chamorey E, Long-Mira E, Lassalle S, Albertini AF, Liolios I, Zahaf K, Picard A, Montaudié H, Lacour JP, Passeron T, Andea AA, Ilie M, Hofman P

doi: 10.1111/jdv.16016.

Related content

Decline of PD-1 positive circulating T regulatory cells predicting more favorable clinical outcome of melanoma patients under immune checkpoint blockade

Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

The helminth-derived peptide GK-1 induces an anti-tumoral CD8 T cell response associated with downregulation of the PD-1/PD-L1 pathway

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma

Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma

Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma

Association of combined PD-L1 expression and tumor-infiltrating lymphocytes features with survival and treatment outcomes in patients with metastatic melanoma